Discovery

  1. Identifying Drug Development Opportunities For DMD With CureDuchenne 8/1/2024

    Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD).

  2. Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene 11/20/2024

    Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on-site during the 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalization impacts patient access, an update on ARM's Grow Internship Program, as well as a few key takeaways from the event that sector professionals can anticipate impacting the CGTs in the next 12 months and beyond.

  3. Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach 6/30/2026

    Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and COO, Jay Hartenbach, to explore how the company is advancing a patient-derived dendritic cell therapy designed to generate a stronger immune response against difficult-to-treat solid tumors, including glioblastoma, pancreatic cancer, and refractory melanoma.

  4. The Future of Rare Diseases with The Jackson Laboratory's Rare Disease Translational Center's Cat Lutz 2/27/2024

    Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz.

  5. Turning the Tumor Microenvironment Against Cancer with MGB's Alexander Cryer, Ph.D. 12/12/2025

    In Episode 118, Host Erin Harris talks to Alexander Cryer, Ph.D., Instructor in Medicine at Mass General Brigham, about a proof-of-concept strategy that reprograms tumor cells with mRNA lipid nanoparticles to overactivate the cGAS-STING pathway, forcing cancer cells to produce and export large amounts of the innate immune agonist cGAMP to stimulate surrounding immune cells and drive anti-tumor immunity.

  6. TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D. 7/4/2024

    KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. 

  7. Advancing Gene Therapy for FTD with Passage Bio's Dr. Will Chou 8/12/2025

    In this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Will Chou, M.D., CEO of Passage Bio about the promise and challenges of developing gene therapies for frontotemporal dementia (FTD), a neurodegenerative disease with strong genetic underpinnings.

  8. Inside Prime Editing With Prime Medicine's Dr. Andrew Anzalone 6/30/2023

    What is prime editing and why is it considered a major technological advancement in gene editing?

  9. Rethinking Large Animal Models in Gene Therapy with Novartis' Ralf Schmid, Ph.D. 7/15/2025

    On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Ralf Schmid, Ph.D., Associate Director of Preclinical Research at Novartis Biomedical Research, about the evolving use of large animal models in gene therapy development.

  10. The Editors' Roundtable: A 2025 Retrospective of the Life Sciences Industry 1/8/2026

    We’re sharing this episode on Cell & Gene: The Podcast because Better Biopharma is a sister podcast within the Life Science Connect family. This conversation speaks directly to the challenges and opportunities our Cell & Gene: The Podcast audience is navigating right now.